Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

SLC1A2 rs3794087 variant and risk for essential tremor

a systematic review and meta-analysis

Jiménez-Jiménez, Félix J.a; Alonso-Navarro, Hortensiaa; García-Martín, Elenab,c; Agúndez, José A.G.b,c

doi: 10.1097/FPC.0000000000000171
ORIGINAL ARTICLES
Buy

Background/objective Recently, a genome-wide association study showed a statistically significant association between the rs3794087 single nucleotide polymorphism (SNP) in the solute carrier family 1 – glial affinity glutamate transporter, member 2 (SLC1A2) and the risk for essential tremor (ET). However, four further association studies showed controversial results.

We carried out a systematic review and a meta-analysis including all the studies published on the risk of ET related to this SNP.

Materials and methods The systematic review was performed using several databases, the meta-analysis was carried out using the software Meta-DiSc 1.1.1, and heterogeneity between studies was tested using the Q statistic.

Results The meta-analysis included five association studies for the SLC1A2 rs3794087 SNP (1925 ET patients, 4914 controls) and the risk for ET. The global diagnostic odds ratio (95% confidence intervals) was 1.08 (0.79–1.48) for the total group. After excluding data from the discovery series (which was responsible for a high degree of heterogeneity), the global diagnostic odds ratio (95% confidence intervals) was 0.96 (0.74–1.23). The separate analysis in White and Asiatic individuals on the frequency of the minor allele of rs3794087 did not show significant differences between ET patients and controls in both subgroups after excluding the discovery series.

Conclusion The results of the meta-analysis suggest that rs3794087 is not associated with the risk for ET.

aSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid

bAMGenomics, Edificio Tajo, Avda. de la Universidad s/n

cDepartment of Pharmacology, University of Extremadura, Cáceres, Spain

Correspondence to Félix J. Jiménez-Jiménez, MD, PhD, C/Marroquina 14, 3° B, E-28030 Madrid, Spain Tel: +34 636 968 395; fax: +34 913 280 704; e-mails: fjavier.jimenez@salud.madrid.org, felix.jimenez@sen.es

Received February 16, 2015

Accepted July 31, 2015

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.